Company: NCEL
Filing Date: 2025-10-24
Form Type: POS AM
Source: 0001213900-25-102149
Chunk: 10

Company: NewcelX Ltd.
Filing Date: 2025-10-24
Form: POS AM
Chunk 10
---
i) a change in par value of the NLS Common Shares, the
preferred shares of NLS, or the NLS Preferred Shares, and the preferred participation certificates of NLS, or the PPCs, to Swiss Franc
(CHF) 0.005; (ii) a consolidation of each of the NLS Common Shares, NLS Preferred Shares and PPCs at a ratio of 1:10, or the Reverse
Split, resulting in a new par value of CHF 0.05; and (iii) an ordinary capital increase, by way of contribution in kind of ordinary
shares of Kadimastem, or the Kadimastem Ordinary Shares, to be issued to Kadimastem shareholders pursuant to the Exchange Ratio under
the Merger Agreement, or the Capital Increase. At the Meeting, the NLS shareholders also authorized a change of NLS’s name to “NewcelX
Ltd.” NLS and Kadimastem expect the Merger to close in October 2025, subject to final Nasdaq approval and satisfaction of
remaining customary closing conditions.

No fractional Common Shares
will be issued in connection with the Merger, and no certificates or scrip for any such fractional shares will be issued. All fractional
share amounts shall be rounded down to the nearest whole based on the total number of Common Shares to be issued to the holders of Kadimastem
Ordinary Shares who would otherwise be entitled to receive a fraction of NLS Common Share. Under the Merger Agreement, any shareholder
receiving Common Shares in excess of a 9.99% beneficial ownership limitation as a result of the Merger, shall be issued instead pre-funded
warrants exercisable for a number of Common Shares equal to such Common Shares in excess of the beneficial ownership limitation, at an
exercise price equal to the par value of the Common Shares as of the Effective Time, which, in any event, shall be no less than CHF 0.0001
per share.

Pursuant to the terms of the
Merger Agreement, prior to or at the Closing, NLS shall designate its transfer agent, or a depository, bank or trust company reasonably
acceptable to NLS to act as the exchange agent in connection with the Merger (the “Exchange Agent”), and enter into an exchange
agreement, in a form reasonably acceptable to NLS, for the payment of the Merger Consideration. Prior to or substantially concurrently
with the Effective Time, NLS